Third, we identified HBV-associated large SVs resulting in 3D genome changes that affect tumor suppressors including PROS1 and NLGN4Y. Finally, we combined public scRNA-seq with our HiC data to further investigate HBV-associated TE reactivation in liver cancer patients, which may indicate better immunotherapeutic responses (41). Here, NLGN4Y is linked to liver cancer.